Genome Canada Statement of cash flows year ended March 31, 2017 (in thousands of dollars) 2017 2016 $ $ Net inflow (outflow) of cash and cash equivalents related to the following activities: Operating Excess of revenues over expenses - - Items not affecting cash Amortization of capital assets 53 50 Change in fair value of investments 58 52 Amortization of deferred contributions (Note 6) (62,162) (53,039) Amortization of deferred contributions related to capital assets (Note 7) (53) (50) Excluded from the increase in deferred contributions (Note 8) (177) (48) (62,281) (53,035) Interest received on investments 509 274 Portfolio investment management (69) (59) Grants received from Government of Canada (Note 6) 66,900 67,400 Deferred contributions related to capital assets 35 9 Change in operating assets and liabilities: Decrease (increase) in other receivable 42 (23) Decrease in prepaid expenses 4 7 (Decrease) increase in accounts payable and accrued liabilities (201) 274 4,939 14,847 Investing Purchase of investments (45,970) (36,898) Proceeds on disposal of investments 29,967 27,981 Purchase of capital assets (35) (9) (16,038) (8,926) Net cash and cash equivalent (outflow) inflow (11,099) 5,921 Cash and cash equivalents, beginning of year 32,736 26,815 Cash and cash equivalents, end of year 21,637 32,736 See accompanying notes to financial statements Page 4